Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like Lysogene Pushes Forward With Sanfilippo Syndrome Study, Establishes Footprint in U.S. October 24, 2017 Bay Area Startup Offers a Compelling Deal to Scientists Hunting for New Drugs April 19, 2017 Genentech Dumps Another $650M in New Haven Biotech Arvinas November 14, 2017
Lysogene Pushes Forward With Sanfilippo Syndrome Study, Establishes Footprint in U.S. October 24, 2017
